Journal
NATURE MEDICINE
Volume 23, Issue 5, Pages 590-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4305
Keywords
-
Funding
- European Economic Community European Coordination Action for Research in Cystic Fibrosis program [EU FP6 SHMCT-2005-018932]
- Specific Targeted Research Project FunMeta [ERC-2011-AdG-293714]
- Italian Cystic Fibrosis Research Foundation
Ask authors/readers for more resources
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) that compromise its chloride channel activity. The most common mutation, p.Phe508del, results in the production of a misfolded CFTR protein, which has residual channel activity but is prematurely degraded. Because of the inherent complexity of the pathogenetic mechanisms involved in CF, which include impaired chloride permeability and persistent lung inflammation, a multidrug approach is required for efficacious CF therapy. To date, no individual drug with pleiotropic beneficial effects is available for CF. Here we report on the ability of thymosin alpha 1 (T alpha 1)-a naturally occurring polypeptide with an excellent safety profile in the clinic when used as an adjuvant or an immunotherapeutic agent- to rectify the multiple tissue defects in mice with CF as well as in cells from subjects with the p.Phe508del mutation. T alpha 1 displayed two combined properties that favorably opposed CF symptomatology: it reduced inflammation and increased CFTR maturation, stability and activity. By virtue of this two-pronged action, T alpha 1 has strong potential to be an efficacious single-molecule-based therapeutic agent for CF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available